NASDAQ: IRWDIronwood Pharmaceuticals Inc Stock
$8.08-0.02 (-0.25%)
Updated Apr 25, 2024
IRWD Price
$8.08
Fair Value Price
$19.60
Market Cap
$1.26B
52 Week Low
$7.53
52 Week High
$15.70
P/E
-1.25x
P/B
-3.65x
P/S
4.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$442.74M
Earnings
-$1.00B
Gross Margin
100%
Operating Margin
-202.63%
Profit Margin
-226.4%
Debt to Equity
-2.36
Operating Cash Flow
$183M
Beta
0.64
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IRWD Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IRWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRWD ($8.08) is undervalued by 58.78% relative to our estimate of its Fair Value price of $19.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IRWD ($8.08) is significantly undervalued by 58.78% relative to our estimate of its Fair Value price of $19.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IRWD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IRWD due diligence checks available for Premium users.
Be the first to know about important IRWD news, forecast changes, insider trades & much more!
IRWD News
Valuation
IRWD fair value
Fair Value of IRWD stock based on Discounted Cash Flow (DCF)
Price
$8.08
Fair Value
$19.60
Undervalued by
58.78%
IRWD ($8.08) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRWD ($8.08) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRWD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.25x
Industry
33.56x
Market
40.97x
IRWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.65x
Industry
2.07x
IRWD's financial health
Profit margin
Revenue
$117.6M
Net Income
-$1.1M
Profit Margin
-0.9%
IRWD's Earnings (EBIT) of -$897.12M... subscribe to Premium to read more.
Interest Coverage Financials
IRWD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$471.1M
Liabilities
$817.4M
Debt to equity
-2.36
IRWD's short-term liabilities ($276.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRWD's long-term liabilities ($541.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$35.8M
Investing
-$4.2M
Financing
-$50.9M
IRWD's operating cash flow ($183.43M)... subscribe to Premium to read more.
Debt Coverage Financials
IRWD vs Pharmaceutical Stocks
Ironwood Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.